Cytokine support + EB-PT-CAR-NK-D + EB-PT-CAR-NK-S + Lymphodepleting chemotherapy for neoplasms

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 1 trial. Early trial in people, checking safety. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 2 Mar 2026: Trial started, NCT07510828
  2. 6 Apr 2026: Trial registered, NCT07510828

The trials

NCT07510828: PRISM-NK: Precision-Matched Allogeneic Single- or Dual-Target CAR-NK Cells for Advanced Solid Tumors

State
Under way
Phase
Phase 1 and Phase 2
People
60 planned
Started
2 Mar 2026
Primary completion
14 Mar 2027
Arms
Arm A: Single-target precision-matched CAR-NK, Arm B: Dual-target precision-matched CAR-NK
Results
None posted
  1. 2 Mar 2026: Trial started
  2. 6 Apr 2026: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Phase 1 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.